Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a wide range of benefits in people with insufficiently controlled type 2 diabetes. Claire Davies provides an overview of these drugs to support safe use in primary care Sodium-glucose cotransporter-2 (SGLT2) inhibitors, sometimes also referred to as ‘gliflozins’ or ‘flozins’, are an established class of medications used for the treatment of insufficiently controlled type 2 diabetes. This article provides a summary of everything nursing staff in primary care need to know about the use of SGLT2 inhibitors for type 2 diabetes to support safe prescribing, monitoring and use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
